Testing effectiveness (Phase 2)UnknownNCT02644655
What this trial is testing
Immunotherapy Using Autologous T Cell-Engineered With CD19-specific Chimeric Antigen Receptor for the Treatment of Recurrent /Refractory B Cell Leukemia
Who this might be right for
Recurrent B-Cell TumorRefractory B-Cell Tumor
Second Military Medical University 20